Early data support Anatare's needle-free insulin device
This article was originally published in Clinica
Executive Summary
Antares Pharma has reported promising preliminary trial data for its needle-free insulin injection system. All patients experienced a significant lowering of blood sugar shortly after each meal when their insulin was administered with the VISION injector, said the Exton, Philadelphia firm. Results showed that the firm's Medi-Jector VISION needle-free injection system average daily blood sugar levels by 17% - from a level of 184mg/dl to 152mg/dl - compared with conventional needle and syringe insulin delivery.